framingham risk score calculator pdf files

Methods: Randomized trials of BP-lowering therapy versus placebo or pretreated subjects in active comparator studies with posttrial follow-up will be identified using a 2-step process. Objective: We aim to investigate the legacy effect of delayed BP-lowering pharmacotherapy in middle-aged individuals (45-65 years) with mildly elevated BP (systolic BP 140-159 mmHg and/or diastolic BP 90-99 mmHg) stratified by absolute risk for primary prevention of CVD, but particularly in the low-risk (<10% five-year absolute risk) group. While BP-lowering drug treatment is beneficial in high-risk individuals at any level of elevated BP, clinicians are concerned about legacy effects on patients with low-to-moderate risk and mildly elevated BP who remain “untreated”. JMIR Bioinformatics and Biotechnology 23 articlesĮmail: Many national and international guidelines recommend that the initiation of blood pressure (BP)-lowering drug treatment for the primary prevention of cardiovascular disease (CVD) should no longer be based on BP level alone, but on absolute cardiovascular risk.JMIR Biomedical Engineering 61 articles.JMIR Perioperative Medicine 69 articles.Journal of Participatory Medicine 71 articles.

JMIR Rehabilitation and Assistive Technologies 177 articles.JMIR Pediatrics and Parenting 230 articles.Interactive Journal of Medical Research 259 articles.JMIR Public Health and Surveillance 964 articles.Journal of Medical Internet Research 6898 articles.

Framingham risk score calculator pdf files